DE-1539

USSN: 10/718,734

LISTING OF CLAIMS:

- 2 -

The following is a listing of claims with claim 3 shown as amended:

In the Claims:

Claims 1-2 (canceled).

3. (currently amended): A compound represented by the following formula (II), and the pharmaceutically acceptable salt thereof:

wherein

R₁-, R₂ is a straight or branched lower alkyl or alkoxy-group having 1 to 6 carbon atoms, a polyethyleneglycol-group selected from the group consisting of an ethyl group, a propyl group, an ethyleneglycol-group, diethyleneglycol-group, triethyleneglycol-group, tetraethyleneglycol-group, hexaethyleneglycol-group, heptaethyleneglycol-group or a methoxyethyleneglycol-group; and

DE-1539

- 3 -

U\$\$N: 10/718,734

R₂ is a straight or branched lower alkyl or alkoxy group having 1 to 6 carbon atoms, a polyethyleneglycol group selected from the group consisting of an ethyl group, a propyl-group, an ethyleneglycol group, diethyleneglycol group, tetraethyleneglycol group, hexaethyleneglycol group, hexaethyleneglycol group, heptaethyleneglycol group or a methoxyethyleneglycol group, which can be chelating with transition metal ion comprising Ni metal ion.

R₁ is a straight or branched lower alkyl or alkoxy group having 1-6 carbon atoms, an ethylene glycol group of formula -(OCH₂CH₂O)_n- where n=4, 6 or 7, an ethylene glycol group, a dietheylene glycol group, a triethylene glycol group or a methoxyethylene glycol group; and

R₂ is an ethylene glycol group of formula -(OCH₂CH₂O)_n- where n=4, 6 or 7, is an ethylene glycol group, which can chelate with transition metal ions comprising Ni metal ion.

Claims 4-8 (canceled).

9. (currently amended): A pharmaceutical composition comprising the compound of formula (II) as set forth in claim 3 or pharmaceutically acceptable salt thereof as an active ingredient together with a pharmaceutically acceptable carrier to treat or prevent breast cancer by way of reproducing singlet state oxygen radical.

DE-1539

- 4 -

USSN: 10/718,734

Claims 10-11 (canceled).

12. (currently amended): A method of treating er preventing breast cancer in human or mammal, wherein the method comprises administering a therapeutically effective amount of the compound of formula of (II) as set forth in claim 3 or pharmaceutically acceptable salt thereof.

Claims 13-48 (canceled).